Resistance to keratolysis boosted by crosslinking

Article

Optimal resistance to in vitro keratolysis by collagenase A can be achieved by collagen crosslinking the deepithelialized anterior corneal surface for 30 minutes, according to a recently published study.

Optimal resistance to in vitro keratolysis by collagenase A can be achieved by collagen crosslinking the deepithelialized anterior corneal surface for 30 minutes, according to a study published in Cornea.

In a basic investigation, Barron artificial anterior chambers were used to perform ex vivo crosslinking of human corneas. The deepithelialized corneas were pretreated with riboflavin solution and irradiated with ultraviolet A (UVA) light for various durations. The corneas were then trephined and incubated with 0.3% collagenase A solution at 37 °C.

It was found that deepithelialized corneas that received no UV light and no riboflavin dissolved in 5.8 ± 0.6 hours. Increased resistance to dissolution was found in the crosslinked corneas, which demonstrated a time to dissolution of 17.8 ± 2.6 hours.

Longer UVA exposure increased the corneal tissues' resistance to collagenase, reaching a plateau at 30 minutes. Crosslinking the anterior corneas only provided the same amount of resistance as crosslinking both the anterior and posterior corneas.

Corneas that had been gamma-irradiated did not benefit from further crosslinking. They dissolved in 5.6 ± 1.2 hours when further crosslinked and 6.1 ± 0.6 hours when not.

To view an abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.